BACKGROUND: Cancer-related cognitive impairment (CRCI) is one of the most serious side effects of cancer that negatively impacts the quality of life of cancer patients and survivors. There is evidence of CRCI in Hodgkin lymphoma patients (HL); however, there is a lack of studies examining the presence of cognitive deficits before starting any treatment in HL patients. METHODS: Forty adult patients (N = 40) newly diagnosed with HL (with no previous cancer diagnoses) and 40 healthy controls (N = 40) matched for age, sex, education, and premorbid intellect completed the neuropsychological battery and subjective and objective measures of affective distress and quality of life. RESULTS: The results showed impairment in three out of six cognitive domains: verbal memory and learning, speed of processing/psychomotor speed, and abstraction/executive functions in the HL patients before the initiation of any treatment. The speed of processing/psychomotor speed domain is negatively correlated with depression. CONCLUSION: Cognitive deterioration in verbal memory and learning and abstraction/executive functions domains in HL patients seems to occur before the initiation of treatment independently of anxiety, depression, or physical symptoms. This suggests that HL itself may cause cognitive deficits in these cognitive domains. However, the underlying causes of CRCI still remain unclear.

1st Faculty of Medicine Charles University 12108 Prague Czech Republic

3rd Faculty of Medicine Charles University 10000 Prague Czech Republic

Center for Advanced Studies of Brain and Consciousness National Institute of Mental Health 25067 Klecany Czech Republic

Department of Clinical Hematology University Hospital Královské Vinohrady Šrobárova 50 10034 Prague Czech Republic

Faculty of Humanities Charles University 18200 Prague Czech Republic

Zobrazit více v PubMed

Janelsins M.C., Kesler S.R., Ahles T.A., Morrow G.R. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int. Rev. Psychiatry. 2014;26:102–113. doi: 10.3109/09540261.2013.864260. PubMed DOI PMC

Olson B., Marks D.L. Pretreatment Cancer-Related Cognitive Impairment-Mechanisms and Outlook. Cancers. 2019;11:687. doi: 10.3390/cancers11050687. PubMed DOI PMC

Wefel J.S., Vardy J., Ahles T., Schagen S.B. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703–708. doi: 10.1016/S1470-2045(10)70294-1. PubMed DOI

Wefel J.S., Kesler S.R., Noll K.R., Schagen S.B. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J. Clin. 2015;65:123–138. doi: 10.3322/caac.21258. PubMed DOI PMC

Gates P., Krishnasamy M., Wilson C., Hawkes E.A., Doré V., Perchyonok Y., Rowe C.C., Walker A.K., Vardy J.L., de Ruiter M.B., et al. Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: A longitudinal feasibility study. Support. Care Cancer. 2022;30:7731–7743. doi: 10.1007/s00520-022-07153-9. PubMed DOI PMC

Janelsins M.C., Mohamed M., Peppone L.J., Magnuson A., Belcher E.K., Melnik M., Dakhil S., Geer J., Kamen C., Minasian L., et al. Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy. J. Natl. Cancer Inst. 2022;114:47–59. doi: 10.1093/jnci/djab133. PubMed DOI PMC

Wouters H., Baars J.W., Schagen S.B. Neurocognitive function of lymphoma patients after treatment with chemotherapy. Acta Oncol. 2016;55:1121–1125. doi: 10.1080/0284186X.2016.1189092. PubMed DOI

Vinokurova E.G., Marchenko A.A., Khrushchev S.O., Olexenko L.V., Rupchev G.E., Vybornykh D.E., Moiseeva T.N. Cognitive impairments in patients with hodgkin’s lymphoma. HemaSphere. 2018;2:22–23.

Trachtenberg E., Mashiach T., Ben Hayun R., Tadmor T., Fisher T., Aharon-Peretz J., Dann E.J. Cognitive impairment in hodgkin lymphoma survivors. Br. J. Haematol. 2018;182:670–678. doi: 10.1111/bjh.15448. PubMed DOI

Magyari F., Ivánka T., Égerházi A., Simon Z., Miltényi Z., Kósa K., Illés Á. Cognitive dysfunction after treatment for hodgkin lymphoma. HemaSphere. 2018;2:22. doi: 10.1097/01.hs9.0000547903.93436.6d. DOI

Magyari F., Virga I., Simon Z., Miltényi Z., Illés A., Kósa K., Ivánka T., Berecz R., Égerházi A., Illés Á. Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary. Support. Care Cancer. 2022;30:5249–5258. doi: 10.1007/s00520-022-06918-6. PubMed DOI PMC

Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J. Clin. Oncol. 2012;30:3675–3686. doi: 10.1200/JCO.2012.43.0116. PubMed DOI PMC

Lange M., Joly F., Vardy J., Ahles T., Dubois M., Tron L., Winocur G., De Ruiter M.B., Castel H. Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. Ann. Oncol. 2019;30:1925–1940. doi: 10.1093/annonc/mdz410. PubMed DOI PMC

Ahles T.A., Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investig. 2001;19:812–820. doi: 10.1081/CNV-100107743. PubMed DOI

Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793. doi: 10.1002/cncr.21234. PubMed DOI

Meadows M.E., Chang G., Jones J.A., Antin J.R., Orav E.J. Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome. Arch. Clin. Neuropsychol. 2013;28:363–374. doi: 10.1093/arclin/acs141. PubMed DOI PMC

Simó M., Root J.C., Vaquero L., Ripollés P., Jové J., Ahles T., Navarro A., Cardenal F., Bruna J., Rodríguez-Fornells A. Cognitive and brain structural changes in a lung cancer population. J. Thorac. Oncol. 2015;10:38–45. doi: 10.1097/JTO.0000000000000345. PubMed DOI PMC

Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. ‘Chemobrain’ in breast carcinoma: A prologue. Cancer. 2004;101:466–475. doi: 10.1002/cncr.20393. PubMed DOI

World Health Organization International Statistical Classification of Diseases and Related Health Problems, 10th Edition. 2016. [(accessed on 2 August 2023)]. Available online: https://icd.who.int/browse10/2016/en.

Preiss M., Bartoš A., Čermáková R., Nondek M., Benešová M., Rodriguez M., Raisová M., Laing H., Mačudová G., Bezdíček O., et al. Neuropsychologická Baterie Psychiatrického Centra Praha: Klinické Vyšetření Základních Kognitivních Funkcí. PCP; Praha, Czech Republic: 2012.

Krámská L. Český Test Čtení Slov. Propsyco; Otrokovice, Czech Republic: 2014. Hodnocení premorbidního intelektu v neuropsychologii.

Rodriguez M., Fajnerová I., Sedláková K., Dorazilová A., Vorácková V., Paštrnák M. Cluster analysis and correlations between cognitive domains: Cognitive performance in a Czech sample of first episodes schizophrenia spectrum disorders—Preliminary results. Psychiatrie. 2017;21:4–11.

Ptáček R., Raboch J., Vnukova M., Hlinka J., Cervenkova M. Standardization of Czech version of beck depression inventory (BDI II) Eur. Psychiatry. 2017;41:S539. doi: 10.1016/j.eurpsy.2017.01.744. DOI

Kamaradova D., Prasko J., Latalova K., Panackova L., Svancara J., Grambal A., Sigmundova Z., Ociskova M., Bares V., Cakirpaloglu S., et al. Psychometric properties of the Czech version of the Beck Anxiety Inventory - comparison between diagnostic groups. Neuro Endocrinol. Lett. 2015;36:706–712. PubMed

Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56. PubMed DOI PMC

Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x. PubMed DOI

Dragomirecká E., Bartoňová J. WHOQOL-BREF, WHOQOL-100: World Health Organization Quality of Life Assessment: Příručka pro Uživatele České Verze Dotazníků Kvality Života Světové Zdravotnické Organizace. Psychiatrické Centrum; Prague, Czech Republic: 2006.

Shilling V., Jenkins V., Morris R., Deutsch G., Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast. 2005;14:142–150. doi: 10.1016/j.breast.2004.10.004. PubMed DOI

Vardy J.L., Dhillon H.M., Pond G.R., Rourke S.B., Bekele T., Renton C., Dodd A., Zhang H., Beale P., Clarke S., et al. Cognitive Function in Patients with Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J. Clin. Oncol. 2015;33:4085–4092. doi: 10.1200/JCO.2015.63.0905. PubMed DOI PMC

Meyers C.A., Byrne K.S., Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995;12:231–235. doi: 10.1016/0169-5002(95)00446-8. PubMed DOI

Baudino B., D’agata F., Caroppo P., Castellano G., Cauda S., Manfredi M., Geda E., Castelli L., Mortara P., Orsi L., et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q. J. Nucl. Med. Mol. Imaging. 2012;56:559–568. PubMed

Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., Whedon M.B., Bivens S., Mitchell T., Greenberg E.R., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 2002;20:485–493. doi: 10.1200/JCO.2002.20.2.485. PubMed DOI

Cimprich B., So H., Ronis D.L., Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology. 2005;14:70–78. doi: 10.1002/pon.821. PubMed DOI

Zabalegui A., Sanchez S., Sanchez P.D., Juando C. Nursing and cancer support groups. J. Adv. Nurs. 2005;51:369–381. doi: 10.1111/j.1365-2648.2005.03508.x. PubMed DOI